Results 161 to 170 of about 184,049 (218)

Distinct Molecular Pathways Supporting Sjögren Disease Clusters and Disease Progression

Arthritis &Rheumatology, EarlyView.
Objective Sjögren disease (SjD) is a heterogeneous autoimmune disease. We aimed to investigate blood transcriptomic signatures and disease progression among three recently defined clusters of patients with SjD: (1) B cell active disease with low symptom burden (BALS), (2) high systemic activity (HSA), and (3) low systemic activity with high symptom ...
Sacha E. Silva‐Saffar, Yann Nguyen, Raphaèle Seror, Jacques‐Eric Gottenberg, Anna Niarakis, Xavier Mariette, Gaetane Nocturne   +6 more
wiley   +1 more source

IFNg_DeepKG: A Novel Model for Identifying Interferon-Gamma-Inducing Epitopes Using Knowledge Graph RAG in Biomedical Applications. [PDF]

J Chem Inf Model
Le VT, Yuune JPT, Ou YY.
europepmc   +1 more source

Navigating adverse immunostimulation: A practical guide for clinical researchers

British Journal of Clinical Pharmacology, EarlyView.
Problem Setting As drug development moves towards more complex products, early clinical development programmes are increasingly hampered by unwanted and/or unexpected activation of the immune system (adverse immune stimulation, AIS). Solution At the Centre for Human Drug Research, we have introduced standardized procedures to make AIS manageable, while
Juliette A. van den Noort, Anouk C. Meijs, Naomi B. Klarenbeek, Matthijs Moerland   +3 more
wiley   +1 more source

Tracheobronchial infectious diseases in adult-onset immunodeficiency with anti-interferon-gamma autoantibodies. [PDF]

BMC Infect Dis
Liang X, Ma N, Liang S, Huang X, Liang H, Wu S, Ning Y, Pang H, Zhang Z, Chen N, Hong L, He Z.   +11 more
europepmc   +1 more source

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

British Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort, Marella C. E. van Ruissen, Lisanne C. A. Smidt, Naomi B. Klarenbeek, Philip H. K. Kremer, Manon A. A. Jansen, Jacobus Burggraaf, Joop M. A. van Gerven, Matthijs Moerland   +8 more
wiley   +1 more source

Pustular reaction in adult-onset immunodeficiency due to anti-interferon-gamma autoantibodies. [PDF]

Front Immunol
Julanon N, Danpanichkul P, Choonhakarn C, Chaowattanapanit S, Anunnatsiri S, Chetchotisakd P, Kiratikanon S, Rujiwetpongstorn R, Tovanabutra N, Chiewchanvit S, Chaiwarith R, Phinyo P, Chuamanochan M.   +12 more
europepmc   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Cost-effectiveness of latent tuberculosis infection screening using interferon-gamma release assays among migrants to Japan: a Markov modelling study incorporating social vulnerability and access barriers. [PDF]

BMJ Open
Kowada A.
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Uncovering a new player in ischemic stroke: a study of intra-arterial interferon-gamma-producing CD14⁺ myeloid cells in hyperacute stroke. [PDF]

J Neuroinflammation
Hernandez K, Plautz EJ, Sharif S, Jones N, Osiah N, Ortega SB.   +5 more
europepmc   +1 more source